Concord Biotech Ltd. (IN:CONCORDBIO)
:CONCORDBIO
Want to see IN:CONCORDBIO full AI Analyst Report?
CONCORDBIO Stock Chart & Stats
₹1338.60
₹62.10(2.74%)
At close: 4:00 PM EST
₹1338.60
₹62.10(2.74%)
Day’s Range― - ―
52-Week Range₹987.05 - ₹2,075.10
Previous CloseN/A
Volume295.44K
Average Volume (3M)12.81K
Market Cap
₹143.77B
Enterprise Value₹140.07B
Total Cash (Recent Filing)₹3.81B
Total Debt (Recent Filing)₹16.07M
Price to Earnings (P/E)54.0
Beta1.13
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.8%
Share Statistics
EPS (TTM)30.92
Shares Outstanding104,616,200
10 Day Avg. Volume31,605
30 Day Avg. Volume12,808
Financial Highlights & Ratios
PEG Ratio-1.36
Price to Book (P/B)5.32
Price to Sales (P/S)10.16
P/FCF Ratio61.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)36.7
Revenue Forecast (FY)₹13.05B
Bulls Say, Bears Say
Bulls Say
Specialized Fermentation API CapabilitySpecialization in complex, fermentation-based APIs creates durable barriers: process know-how, scale-up expertise and regulatory familiarity make switching costly for customers and support long product lifecycles, recurring contract opportunities and pricing resilience over multi‑year horizons.
Conservative Balance SheetVery low leverage materially reduces financial distress risk and preserves strategic optionality. A conservative capital structure supports steady R&D and capex funding, easier access to partner or contract manufacturing agreements, and resilience across industry cycles over the next several quarters.
Solid Cash Generation & ProfitabilityConsistent operating cash flow that generally outpaces reported earnings and a recent FCF rebound indicate underlying earnings quality. This sustained cash generation supports reinvestment into process development and capacity, and underpins long-term commercial execution and shareholder returns.
Bears Say
Recent Revenue DeclineA reversal to annual revenue decline signals weakening demand or product mix shifts that can constrain growth visibility. If structural, this reduces runway for margin recovery and new investment, pressures future scale benefits, and may require strategic responses to restore multi-year top-line momentum.
Margin Compression From Peak LevelsCompression from prior peak margins suggests less pricing power or rising cost pressures relative to earlier years. Sustained margin erosion would lower free cash flow and return on capital, limiting ability to fund capacity expansion or absorb cyclical downturns over the medium term.
Free Cash Flow VolatilityIntermittent negative FCF and year-to-year swings indicate uneven reinvestment needs or working-capital swings. Persistent volatility reduces predictability for dividends, buybacks or capex and can force financing choices that impair strategic flexibility during multi‑quarter industry headwinds.
Concord Biotech Ltd. News
CONCORDBIO FAQ
What was Concord Biotech Ltd.’s price range in the past 12 months?
Concord Biotech Ltd. lowest stock price was ₹987.05 and its highest was ₹2075.10 in the past 12 months.
What is Concord Biotech Ltd.’s market cap?
Concord Biotech Ltd.’s market cap is ₹143.77B.
When is Concord Biotech Ltd.’s upcoming earnings report date?
Concord Biotech Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 50 days.
How were Concord Biotech Ltd.’s earnings last quarter?
Concord Biotech Ltd. released its earnings results on May 29, 2026. The company reported ₹8.5 earnings per share for the quarter, missing the consensus estimate of ₹8.9 by -₹0.4.
Is Concord Biotech Ltd. overvalued?
According to Wall Street analysts Concord Biotech Ltd.’s price is currently Overvalued.
Does Concord Biotech Ltd. pay dividends?
Concord Biotech Ltd. pays a Notavailable dividend of ₹7.55 which represents an annual dividend yield of 0.8%. See more information on Concord Biotech Ltd. dividends here
What is Concord Biotech Ltd.’s EPS estimate?
Concord Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Concord Biotech Ltd. have?
Concord Biotech Ltd. has 104,616,200 shares outstanding.
What happened to Concord Biotech Ltd.’s price movement after its last earnings report?
Concord Biotech Ltd. reported an EPS of ₹8.5 in its last earnings report, missing expectations of ₹8.9. Following the earnings report the stock price went down -4.598%.
Which hedge fund is a major shareholder of Concord Biotech Ltd.?
Currently, no hedge funds are holding shares in IN:CONCORDBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Concord Biotech Ltd.
Established in 1984 and headquartered in Ahmedabad, India, Concord Biotech Limited operates as a biopharmaceutical enterprise focused on the discovery, development, production, and global commercialization of pharmaceutical goods. A core component of its offerings comprises fermentation-derived active pharmaceutical ingredients (APIs) applied across various critical medical fields. These include immunosuppressive agents (such as tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus), anti-bacterial compounds (like mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin), oncology treatments (including temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin), and antifungal medications (such as anidulafungin, caspofungi, and micafungin sodium). Additionally, the company supplies other specialized APIs like lovastatin and pravastatin sodium. Concord Biotech further augments its services by providing contract research and manufacturing solutions (CRAMS), particularly emphasizing fermentation and semi-synthesis capabilities.
Technical Analysis
Biocon Limited
―
Blue Jet Healthcare Limited
―
Jubilant Ingrevia Ltd.
―
Piramal Pharma Limited
―
Syngene International Ltd.
―